Glenmark Pharmaceuticals Ltd. (GLENMARK) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,393.00",
    "chg": 14,
    "chgp": "0.59%",
    "dir": 1,
    "prev_price": "2,379.00",
    "mcapval": "67,198.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE935A01035",
    "curr_date": "May 21",
    "curr_time": "",
    "bse_nse_vol": "3.97 lacs",
    "exc_status": "Active",
    "traded_date": "May 21, 2026",
    "traded_date_str": "2026 05 21",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "SM",
      "url": "https://www.marketsmojo.com/mojopro/stock-of-the-month",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-1&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Signalling Bullish Market Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-signalling-bullish-market-positioning-4003279",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_oi_spurts_by_underlying_4003279.png",
        "date": "2026-05-21 15:00:29",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, with a 17.37% increase to 47,848 contracts from the previous 40,766. This spike, coupled with rising volumes and strong price performance near its 52-week high, suggests growing bullish sentiment and strategic positioning by market participants in the mid-cap pharmaceutical stock."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Signalling Bullish Market Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-signalling-bullish-market-positioning-4003182",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_oi_spurts_by_underlying_4003182.png",
        "date": "2026-05-21 14:00:20",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting heightened market participation and a potential shift in investor sentiment towards a bullish stance. The stock’s recent performance, coupled with increased volumes and rising investor interest, suggests that market participants are positioning for an upward trajectory in the near term."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Signalling Strong Market Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-signalling-strong-market-positioning-4003116",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_oi_spurts_by_underlying_4003116.png",
        "date": "2026-05-21 13:00:15",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest (OI) in its derivatives segment, reflecting heightened market activity and a potential shift in investor sentiment. The pharmaceutical mid-cap, trading close to its 52-week high, has seen a 13.19% increase in OI, accompanied by robust volume and rising delivery volumes, signalling increased bullish positioning among traders and investors."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Signalling Bullish Market Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-signalling-bullish-market-positioning-4003043",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_oi_spurts_by_underlying_4003043.png",
        "date": "2026-05-21 12:00:11",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased investor interest and potential directional bets. The stock’s rising volumes and improved market positioning underscore a bullish sentiment, supported by strong technicals and a recent upgrade to a Strong Buy rating by MarketsMOJO."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Signal Strong Buy",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-technical-momentum-shifts-signal-strong-buy-4002159",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_technicaldot_4002159.png",
        "date": "2026-05-21 08:02:53",
        "description": "Glenmark Pharmaceuticals Ltd. has experienced a nuanced shift in its technical momentum, reflecting a transition from a bullish to a mildly bullish trend. Despite a minor day decline of 1.15%, the mid-cap pharmaceutical stock continues to outperform the broader market, supported by robust technical indicators and a strong fundamental backdrop."
      },
      {
        "title": "When is the next results date for Glenmark Pharmaceuticals Ltd.?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-glenmark-pharmaceuticals-ltd-4001752",
        "imagepath": "",
        "date": "2026-05-20 23:19:04",
        "description": "The next results date for Glenmark Pharmaceuticals Ltd. is scheduled for 29 May 2026...."
      },
      {
        "title": "Glenmark Pharmaceuticals Upgraded to Strong Buy on Robust Valuation and Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-upgraded-to-strong-buy-on-robust-valuation-and-financials-4000375",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_mojoScore_4000375.png",
        "date": "2026-05-20 08:23:51",
        "description": "Glenmark Pharmaceuticals Ltd. has been upgraded from a Buy to a Strong Buy rating by MarketsMojo, reflecting significant improvements across valuation, financial trends, quality metrics, and technical indicators. The mid-cap pharmaceutical company’s enhanced mojo score of 81.0 underscores its compelling investment case amid robust earnings growth, attractive valuation multiples, and sustained outperformance against benchmarks."
      },
      {
        "title": "Glenmark Pharmaceuticals Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-valuation-shifts-signal-renewed-price-attractiveness-3996005",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_valuationdot_3996005.png",
        "date": "2026-05-18 08:01:53",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable shift in its valuation parameters, moving from an already attractive stance to a very attractive one. This change is underscored by key metrics such as the price-to-earnings (P/E) ratio and price-to-book value (P/BV), which now position the mid-cap pharmaceutical player favourably against both its historical averages and peer group benchmarks. Despite a minor day decline of 0.66%, the stock’s valuation improvement and robust financial fundamentals continue to support a positive outlook."
      },
      {
        "title": "Glenmark Pharmaceuticals Downgraded to Buy Amid Valuation and Technical Adjustments",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-downgraded-to-buy-amid-valuation-and-technical-adjustments-3992131",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GlenmarkPharmac_mojoScore_3992131.png",
        "date": "2026-05-15 08:12:51",
        "description": "Glenmark Pharmaceuticals Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating adjusted from Strong Buy to Buy as of 14 May 2026. This recalibration reflects a nuanced assessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. While the company continues to demonstrate robust financial performance and operational strength, evolving market valuations and technical indicators have prompted a more cautious stance from analysts."
      }
    ],
    "total": 545,
    "sid": "780863",
    "stock_news_url": "https://www.marketsmojo.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "details": "Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 26, 2019, titled \"Glenmark Pharmaceuticals receives ANDA approval for Metformin Hydrochloride Extended-Release Tablets USP,",
      "source": "NSE",
      "caption": "Glenmark Pharmaceuticals Limited - Press Release",
      "datetime": "26-Nov-2019"
    },
    {
      "details": "Glenmark Pharmaceuticals Limited has informed the Exchange regarding Grant of 20000 Options.",
      "source": "NSE",
      "caption": "Glenmark Pharmaceuticals Limited - ESOP/ESOS/ESPS",
      "datetime": "15-Nov-2019"
    },
    {
      "details": "Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015",
      "source": "NSE",
      "caption": "Glenmark Pharmaceuticals Limited - Trading Window",
      "datetime": "06-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "29 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 03 Oct 25",
          "dt": "2025-10-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Signalling Bullish Market Positioning

2026-05-21 15:00:29

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, with a 17.37% increase to 47,848 contracts from the previous 40,766. This spike, coupled with rising volumes and strong price performance near its 52-week high, suggests growing bullish sentiment and strategic positioning by market participants in the mid-cap pharmaceutical stock.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Signalling Bullish Market Positioning

2026-05-21 14:00:20

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting heightened market participation and a potential shift in investor sentiment towards a bullish stance. The stock’s recent performance, coupled with increased volumes and rising investor interest, suggests that market participants are positioning for an upward trajectory in the near term.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Signalling Strong Market Positioning

2026-05-21 13:00:15

Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest (OI) in its derivatives segment, reflecting heightened market activity and a potential shift in investor sentiment. The pharmaceutical mid-cap, trading close to its 52-week high, has seen a 13.19% increase in OI, accompanied by robust volume and rising delivery volumes, signalling increased bullish positioning among traders and investors.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Signalling Bullish Market Positioning

2026-05-21 12:00:11

Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased investor interest and potential directional bets. The stock’s rising volumes and improved market positioning underscore a bullish sentiment, supported by strong technicals and a recent upgrade to a Strong Buy rating by MarketsMOJO.

Read full news article

Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Signal Strong Buy

2026-05-21 08:02:53

Glenmark Pharmaceuticals Ltd. has experienced a nuanced shift in its technical momentum, reflecting a transition from a bullish to a mildly bullish trend. Despite a minor day decline of 1.15%, the mid-cap pharmaceutical stock continues to outperform the broader market, supported by robust technical indicators and a strong fundamental backdrop.

Read full news article

When is the next results date for Glenmark Pharmaceuticals Ltd.?

2026-05-20 23:19:04

The next results date for Glenmark Pharmaceuticals Ltd. is scheduled for 29 May 2026....

Read full news article

Glenmark Pharmaceuticals Upgraded to Strong Buy on Robust Valuation and Financials

2026-05-20 08:23:51

Glenmark Pharmaceuticals Ltd. has been upgraded from a Buy to a Strong Buy rating by MarketsMojo, reflecting significant improvements across valuation, financial trends, quality metrics, and technical indicators. The mid-cap pharmaceutical company’s enhanced mojo score of 81.0 underscores its compelling investment case amid robust earnings growth, attractive valuation multiples, and sustained outperformance against benchmarks.

Read full news article

Glenmark Pharmaceuticals Valuation Shifts Signal Renewed Price Attractiveness

2026-05-18 08:01:53

Glenmark Pharmaceuticals Ltd. has witnessed a notable shift in its valuation parameters, moving from an already attractive stance to a very attractive one. This change is underscored by key metrics such as the price-to-earnings (P/E) ratio and price-to-book value (P/BV), which now position the mid-cap pharmaceutical player favourably against both its historical averages and peer group benchmarks. Despite a minor day decline of 0.66%, the stock’s valuation improvement and robust financial fundamentals continue to support a positive outlook.

Read full news article

Glenmark Pharmaceuticals Downgraded to Buy Amid Valuation and Technical Adjustments

2026-05-15 08:12:51

Glenmark Pharmaceuticals Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating adjusted from Strong Buy to Buy as of 14 May 2026. This recalibration reflects a nuanced assessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. While the company continues to demonstrate robust financial performance and operational strength, evolving market valuations and technical indicators have prompted a more cautious stance from analysts.

Read full news article

View All News